Analysis of the current market price of Everolimus per box and purchasing channels

Everolimus (Everolimus) is an oral mTOR inhibitor that is widely used in the clinical treatment of renal cell carcinoma, breast cancer, neuroendocrine tumors and the prevention of organ transplant rejection. In China, everolimus has been officially launched and included in the medical insurance directory, which means that eligible patients can reduce their financial burden through medical insurance reimbursement.

In the domestic market, everolimus mainly comes in two specifications: 2.5mg30 tablets and 5mg30 tablets. The price of 2.5mg specification is about 2,000 yuan, while the price of 5mg specification is between three and four thousand yuan. The price will fluctuate due to differences in hospital procurement channels, regional drug price adjustments and medical insurance policies. Patients should confirm the latest selling price and medical insurance reimbursement ratio with the hospital pharmacy before purchasing to reasonably plan treatment costs.

In overseas markets, everolimus also has a variety of generic versions. The Lao Lucius version is available in two specifications: 5mg 30 tablets and 10mg 30 tablets. The prices are about 8900 yuan and 1,700 yuan respectively. Right; the Indian version provides 5mg10 tablets and 10mg10 tablets, with prices ranging from 7 to 800 yuan and 1,200 to 1,800 yuan respectively. Compared with domestic original drugs, these overseas generic drugs are more economical in price, but they need to be obtained through formal import channels or overseas pharmacies.

Overall, everolimus has a stable supply in China and can reduce patients’ financial pressure through medical insurance reimbursement. Overseas generic drugs provide lower-priced options, but attention must be paid to the legality of the purchasing channels and the quality of the drugs. When taking medicine, patients should reasonably choose specifications and purchase channels based on doctor's advice, medical insurance policies and personal financial conditions to ensure the continuity and safety of treatment.

Reference link:https://www.drugs.com